UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22

The Journal of experimental medicine, 2014-07, Vol.211 (8), p.1571-1583

2014

Volltextzugriff (PDF)

Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease

PloS one, 2012-07, Vol.7 (7), p.e41594-e41594

2012

Volltextzugriff (PDF)

Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review

Journal of medical Internet research, 2019-08, Vol.21 (8), p.e14630-e14630

2019

Volltextzugriff (PDF)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Journal of Crohn's and colitis, 2022-08, Vol.16 (8), p.1222-1234

2022

Volltextzugriff (PDF)

Adherent-invasive E. coli metabolism of propanediol in Crohn’s disease regulates phagocytes to drive intestinal inflammation

Cell host & microbe, 2021-04, Vol.29 (4), p.607-619.e8

2021

Volltextzugriff (PDF)

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

Alimentary pharmacology & therapeutics, 2020-12, Vol.52 (11-12), p.1658-1675

2020

Volltextzugriff (PDF)

Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation

Inflammatory bowel diseases, 2014-11, Vol.20 (11), p.1919-1932

2014

Volltextzugriff (PDF)

Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont Escherichia coli and Host Response

Antibiotics (Basel), 2020-08, Vol.9 (8), p.462

2020

Volltextzugriff (PDF)

5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity

Journal of antibiotics, 2018-11, Vol.71 (11), p.950-961

2018

Volltextzugriff (PDF)

Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps

Antimicrobial Agents and Chemotherapy, 2013-02, Vol.57 (2), p.811-817

2013

Volltextzugriff (PDF)

Rifaximin decreases virulence of Crohn’s disease-associated Escherichia coli and epithelial inflammatory responses

Journal of antibiotics, 2018-05, Vol.71 (5), p.485-494

2018

Volltextzugriff (PDF)

ID1 Is a Functional Marker for Intestinal Stem and Progenitor Cells Required for Normal Response to Injury

Stem cell reports, 2014-11, Vol.3 (5), p.716-724

2014

Volltextzugriff (PDF)

Immune regulation by fungal strain diversity in inflammatory bowel disease

Nature (London), 2022-03, Vol.603 (7902), p.672-678

2022

Volltextzugriff (PDF)

Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn's disease

JCI insight, 2022-05, Vol.7 (10)

2022

Volltextzugriff (PDF)

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2020-10, Vol.159 (4), p.1541-1544.e2

2020

Volltextzugriff (PDF)

Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis

Immunity (Cambridge, Mass.), 2018-12, Vol.49 (6), p.1077-1089.e5

2018

Volltextzugriff (PDF)

Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease

World journal of gastroenterology : WJG, 2022-09, Vol.28 (33), p.4834-4845

2022

Volltextzugriff (PDF)

Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry

The American journal of gastroenterology, 2024-03, Vol.119 (3), p.468-476

2024

Volltextzugriff (PDF)

S719 Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results From the PIANO Registry

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e502-e503

2022

Volltextzugriff (PDF)

Ulcerative Colitis Care Pathway

Gastroenterology (New York, N.Y. 1943), 2015-07, Vol.149 (1), p.238-245

2015

Volltextzugriff (PDF)

Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease

Inflammatory bowel diseases, 2021-08, Vol.27 (9), p.1443-1451

2021

Volltextzugriff (PDF)

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination

Clinical gastroenterology and hepatology, 2022-06, Vol.20 (6), p.e1493-e1499

2022

Volltextzugriff (PDF)

CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2022-10, Vol.163 (4), p.950-964

2022

Volltextzugriff (PDF)

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

Clinical gastroenterology and hepatology, 2021-11, Vol.19 (11), p.2324-2332.e6

2021

Volltextzugriff (PDF)

Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease

Inflammatory bowel diseases, 2022-12, Vol.28 (12), p.1865-1871

2022

Volltextzugriff (PDF)

1 – 25 von 289

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(247)

Publikationsform

Artikel
(203)
Buchkapitel
(79)
Berichte
(4)
Bücher
(3)

Sprache

Englisch
(289)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22

Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease

Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Adherent-invasive E. coli metabolism of propanediol in Crohn’s disease regulates phagocytes to drive intestinal inflammation

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation

Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont Escherichia coli and Host Response

5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity

Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps

Rifaximin decreases virulence of Crohn’s disease-associated Escherichia coli and epithelial inflammatory responses

ID1 Is a Functional Marker for Intestinal Stem and Progenitor Cells Required for Normal Response to Injury

Immune regulation by fungal strain diversity in inflammatory bowel disease

Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn's disease

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis

Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease

Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry

S719 Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results From the PIANO Registry

Ulcerative Colitis Care Pathway

Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination

CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease

Suchergebnisse filtern